Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
71 stopped studies mapped to Esophageal Carcinoma and descendants · 94% state a reason
Over the 71 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01498757 | Genome-wide Association Study | — | withdrawn | Dec 23, 2011 | Samsung Medical Center | Registration poor | Other (stated, no rule matched) |
| NCT01248299 | Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type…(E-DIS) | Phase 2 | terminated | Nov 25, 2010 | Centre Oscar Lambret | not stated | Not stated |
| NCT03122548 | Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction… | Phase 2 | terminated | Apr 21, 2017 | Aduro Biotech, Inc. | Low enrollment and lack of clinical activity in other CRS-207 studies. | Enrollment / accrual |
| NCT03223662 | Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment… | Phase 2 | terminated | Jul 21, 2017 | National Cancer Institute (NCI) | Principal Investigator left the NIH. | Investigator |
| NCT02234180 | Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or… | Phase 2 | terminated | Sep 9, 2014 | Academic and Community Cancer Research United | not stated | Not stated |
| NCT03220009 | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in… | Phase 2 | withdrawn | Jul 18, 2017 | National Cancer Institute (NCI) | The study was never approved by CTEP neither was it ever activated | Other (stated, no rule matched) |
| NCT01608464 | Pre-op Chemo-RT w/CDDP/5FU vs Chemo w/ Docetaxel/Irinotecan in PET Non Responder… | Phase 2 | terminated | May 31, 2012 | King Faisal Specialist Hospital & Research Center | poor accrual | Enrollment / accrual |
| NCT02638909 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal… | Phase 2 | terminated | Dec 23, 2015 | Criterium, Inc. | Lack of Enrollment | Enrollment / accrual |
| NCT01627379 | Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic…(POWER) | Phase 3 | terminated | Jun 25, 2012 | AIO-Studien-gGmbH | Sponsor decision due to recommendation of the IDMC. | Sponsor / business decision |
| NCT02392377 | Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal… | Phase 2 | terminated | Mar 19, 2015 | Case Comprehensive Cancer Center | Slow accrual | Enrollment / accrual |
| NCT03307941 | Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced…(ARTEMIS-Eso) | Phase 1 / Phase 2 | withdrawn | Oct 12, 2017 | Jules Bordet Institute | Suspended collaboration with the company providing the study drug | Sponsor / business decision |
| NCT01740375 | Role of Esophagectomy in Complete Responders to CCRT(ESOPRESSO) | Phase 3 | terminated | Dec 4, 2012 | Asan Medical Center | slow recruitment | Enrollment / accrual |
| NCT02023541 | Proton Beam Therapy to Treat Esophageal Cancer | Phase 1 | terminated | Dec 30, 2013 | Washington University School of Medicine | Lack of insurance coverage for proton beam treatment | Other (stated, no rule matched) |
| NCT02033538 | Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell… | Phase 2 | withdrawn | Jan 10, 2014 | Zhejiang University | This clinical trial was closed due to slow recruitment of patients. | Enrollment / accrual |
| NCT02034968 | Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced… | Phase 2 | withdrawn | Jan 14, 2014 | Zhejiang University | No recruitment | Enrollment / accrual |
| NCT02041819 | Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of… | Phase 2 | withdrawn | Jan 22, 2014 | Zhejiang University | No recruitment | Enrollment / accrual |
| NCT02011594 | Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma | Phase 2 | withdrawn | Dec 13, 2013 | Zhejiang University | There was no participants enrolled in this clinical trial. | Enrollment / accrual |
| NCT00636298 | Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's… | Phase 2 | withdrawn | Mar 14, 2008 | Emory University | lack of funding | Funding |
| NCT00098527 | FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction… | Phase 2 | terminated | Dec 8, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00061958 | Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or… | Phase 2 | terminated | Jun 6, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00239200 | Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus | Phase 2 | terminated | Oct 14, 2005 | University of Michigan Rogel Cancer Center | notification from sponsor | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated May 21, 2019source: clinicaltrials